Q2 STOCKS TO BUY

2 Biotechs That Could Bomb After Earnings

If history is any indicator, things could get ugly after earnings for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

Nov 4, 2016 at 12:24 PM
facebook X logo linkedin


Earnings season has resulted in some sharp moves for biotech stocks. For that reason, it's worth noting next Monday boasts a deep lineup of drugmakers ready to enter the earnings confessional. Among them are ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA).

ACAD will report earnings after the close on Monday. Historically, most of the shares' big post-event swings have been to the downside. Looking back eight quarters, the biotech stock has plunged in the session following earnings half the time, with an average single-day loss of 8.8%. That compares with an average gain of just 1.6% after the other four reports.

Ahead of earnings, ACAD is up sharply. At midday, the shares have added 4.3% to trade at $21.76. Yet, the stock has also sold off considerably, relative to its most recent high of $36.59 in late September, shedding about two-fifths of its value in less than two months.

Understandably, short sellers have been piling on ACAD. Over 19 million shares have been sold short, or about 22% of the stock's float. At the same time, these bearish bettors may be hedging their positions ahead of earnings, via protective calls. During the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), traders have bought to open 10.60 ACADIA Pharmaceuticals Inc. calls for every put -- with a recent rush toward bullish bets inspired by buyout buzz.

Turning to fellow biotech ARIA, the company is scheduled to report earnings Monday morning. In the past, things haven't been pretty for the shares in the immediate aftermath of these events. Specifically, the stock has finished six of the past eight post-earnings sessions lower.

In light of this, it makes sense that options traders have been targeting ARIA puts over calls. The stock's 20-day ISE/CBOE/PHLX put/call volume ratio checks in at 1.59, while its front-month gamma-weighted Schaeffer's put/call open interest ratio (SOIR) -- which measures near-the-money open interest in the November series -- is a top-heavy 2.06.

Today, Ariad Pharmaceuticals, Inc. is 1.4% higher at $8.78, bringing its year-to-date gains beyond 40%. However, the biotech stock has had a brutal quarter, down about 36% since the start of October, and is now struggling to overcome its 160-day moving average.

Let us help you profit from market volatility. Target big gains in short order with a 30-day trial of Schaeffer's Weekly Volatility Trader!

 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter